These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29020156)

  • 1. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Powderly WG; Naggie S; Kim AY; Vargas HE; Chung RT; Lok AS
    Clin Infect Dis; 2017 Nov; 65(11):1773-1775. PubMed ID: 29020156
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.
    Yeon JE
    Clin Mol Hepatol; 2018 Sep; 24(3):278-293. PubMed ID: 29716179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
    McConachie SM; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Retreatment of hepatitis C virus Patients in whom Direct-Acting Antivirals have Failed.
    López Zúñiga MÁ; Prieto Moreno M; de Jesús S; López Ruz MÁ
    Gastroenterol Hepatol; 2019 Nov; 42(9):558-561. PubMed ID: 31320125
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 8. Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response.
    Sacks HS
    Ann Intern Med; 2017 Jul; 167(2):JC3. PubMed ID: 28715825
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C.
    Rossotti R; Garcia-Fraile Fraile LJ; Baiguera C; Puoti M
    J Clin Pharmacol; 2017 Jul; 57(7):931-932. PubMed ID: 28467638
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Mücke MM; Mücke VT; Vermehren J
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1573-1574. PubMed ID: 29878415
    [No Abstract]   [Full Text] [Related]  

  • 13. [Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
    Weiland O
    Lakartidningen; 2014 Nov; 111(51-52):2280-1. PubMed ID: 25423337
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Yu ML
    Gastroenterology; 2017 Sep; 153(3):867. PubMed ID: 28781223
    [No Abstract]   [Full Text] [Related]  

  • 15. Do direct acting antivirals cure chronic hepatitis C?
    Jakobsen JC; Nielsen EE; Koretz RL; Gluud C
    BMJ; 2018 May; 361():k1382. PubMed ID: 29748173
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?
    Maan R; Feld JJ
    Gastroenterology; 2017 Oct; 153(4):890-892. PubMed ID: 28867275
    [No Abstract]   [Full Text] [Related]  

  • 17. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
    Feld JJ
    Gastroenterology; 2012 May; 142(6):1356-9. PubMed ID: 22537443
    [No Abstract]   [Full Text] [Related]  

  • 19. After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver.
    Kwo PY; Lacerda MA
    Gastroenterology; 2016 Oct; 151(4):582-4. PubMed ID: 27590790
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct-acting antivirals for acute HCV: how short can we go?
    Martinello M; Grebely J; Matthews GV
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):316-318. PubMed ID: 28397692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.